Aptoil

Aptoll is a clinical-stage biotechnology company based in South Korea that focuses on the development of aptamer-based therapeutics for inflammatory diseases and cancer. The company's core technology centers on a proprietary aptamer discovery platform that identifies high-affinity ligands for challenging therapeutic targets, specifically Toll-like receptors (TLRs). Its lead candidate, APT-101, is a TLR4 antagonist currently being evaluated for the treatment of ischemic stroke and other inflammatory conditions like myocardial infarction. Aptoll's pipeline also includes programs in immuno-oncology and fibrosis, aiming to provide targeted alternatives to traditional small molecule and antibody therapies.